incorpor tafasitamab model
interest opportun subject commerci
follow complet tafasitamab licens transact morphosi
updat model reflect deal recal januari
announc compani would pay up-front licens tafasitamab
morphosi grant exclus commerci right ou profit share
econom us sale well small equiti stake tafasitamab
antibodi treat patient r/r dlbcl cell malign believ
tafasitamab like approv gener ww unadjust
sale view revenu diversif away jakafi relianc
increment posit believ transact introduc degre commerci
execut risk abl gener return invest greater
up-front cost reduc tp reflect use cash
execut risk partial off-set tafasitamab contribut begin
tafasitamab pass futil analysi phase trial bla submit
recent novemb phase trial b-mind tafasitamab dlbcl success
pass pre-plan interim futil analysi increas patient
b-mind trial compar efficaci tafasitamab plu bendamustin
rituximab plu bendamustin patient r/r dlbcl morphosi submit
bla fda base primari analysi data phase l-mind trial fda
grant prioriti review set pdufa date august
model updat risk weve updat model includ tafasitamab assum
approv launch gener unadjust ww sale
appli po adjust assum use r/r dlbcl patient
treat cell therapi novel agent receiv share us
tafasitamab profit pay assum royalti tafasitmab ou sale weve
increas wacc reflect commerci execut risk ep
unchang minor adjust risk includ commerci clinic regulatori
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
incyt corp biopharmaceut compani engag
discoveri develop commerci proprietari therapeut
oncolog hematolog dermatolog
blue sky upsid case valuat base fda
approv pemigatinib cholangiocarcinoma within next
month also assum better expect jakafi revenu
grey sky downsid valuat assum fda
approv pemigatinib grey sky also assum neg data readout
pemigatinib urotheli cancer also assum jakafi revenu
lower expect
 close
expect approv late follow posit updat prioriti review
morphosi present interim data patient l-mind trial
combin tafasitamab lenalidomid patient r/r dlbcl two prior
line therapi data posit orr ci cr rate
median dor median month march fda grant
tafasitamab prioriti review pdufa date august
deal term incyt gain exclus ou right co-commerci us
deal morphosi entitl mileston payment make equiti
invest morphosi along up-front payment us
morphosi book us revenu share profit basi ou
revenu book royalti mid-teen mid-twenti paid morphosi
furthermor cover develop cost ww vs morphosi
respons futur develop cost trial ou
model chang weve updat model includ tafasitamab assum approv
launch gener unadjust ww sale
appli po adjust expect ou approv submiss
assum use r/r dlbcl patient treat cell therapi novel agent
receiv share us tafasitamab profit pay assum royalti
tafasitmab ou sale weve increas wacc reflect increas
incyt corpor million actualactualpriorcurrentchangejakafi ruxolitinib sale ruxolitinib royalti revenu loss incom cs dilut cs charl martineau pm univers toronto march
valuat one-year price target deriv sum-of-the-part dcf analysi
use discount rate termin growth rate year
experi commerci jakafi view best-in-class product current
minim near-term competit threat forecast cash flow account
known expect competit launch patent expir beyond appli
termin growth believ abl replac cash flow lost eros via
busi develop continu invest
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
